




Instance: composition-en-74778e8109bf478af8bf20ce15b25c4c
InstanceOf: CompositionUvEpi
Title: "Composition for copiktra Package Leaflet"
Description:  "Composition for copiktra Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpe9b880749c9b002511477c4f4dcdb6c9)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - copiktra"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Copiktra is and what it is used for  </li>
<li>What you need to know before you take Copiktra  </li>
<li>How to take Copiktra </li>
<li>Possible side effects  </li>
<li>How to store Copiktra  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What copiktra is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What copiktra is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Copiktra is a cancer medicine that contains the active substance duvelisib. It works by blocking the 
effects of enzymes needed for the growth and survival of B-lymphocytes (a type of white blood cell). 
These enzymes are overactive in certain cancerous white blood cells and by blocking them Copiktra 
can kill and reduce the number of cancerous B-lymphocytes. </p>
<p>Copiktra is used for the treatment of cancers of B-lymphocytes called<br />
  chronic lymphocytic leukaemia (or small lymphocytic lymphoma) 
  follicular leukaemia.  </p>
<p>In these diseases the B-lymphocytes multiply too quickly and live too long, so there are too many of 
them in the blood or lymph nodes.  Copiktra is used when patients have previously been given at least 
2 other therapies that did not work or are no longer working. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take copiktra"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take copiktra"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Copiktra 
- if you are allergic to duvelisib or any of the other ingredients of this medicine (listed in section 6). 
If you are not sure, talk to your doctor before taking Copiktra. </p>
<p>Warnings and precautions </p>
<p>Talk to your doctor or pharmacist before taking Copiktra, 
- if you have an infection. This must be treated before you start taking Copiktra. 
- if you have intestinal problems 
- if you have lung or breathing problems </p>
<p>Infections 
Infections are common during Copiktra treatment, and can be serious and can lead to death. Tell your 
doctor, pharmacist, or nurse right away if you have fever, chills, or other signs of an infection during 
treatment with Copiktra. Your doctor may prescribe another medicine while you are taking Copiktra, 
to prevent certain types of infection. </p>
<p>Diarrhoea or inflammation of your intestine<br />
Diarrhoea or inflammation of your intestine (colitis) is common during Copiktra treatment, and can be 
serious and can lead to death. Tell your doctor or pharmacist right away if you have any new or 
worsening diarrhoea, you pass mucus or blood when going to the toilet, or if you have severe 
abdominal (stomach area) pain. Your doctor or pharmacist should prescribe medicine to help your 
diarrhoea and check you at least weekly. If your diarrhoea is severe or anti-diarrhoea medicines do not 
work, you may need treatment with a steroid medicine. </p>
<p>Skin reactions<br />
Copiktra can cause rashes and other skin reactions that can be serious and can lead to death. Tell your 
doctor or pharmacist right away if you get new or worsening skin rash, or other skin reactions during 
treatment with Copiktra, including:</p>
<ul>
<li>painful sores or ulcers on your skin, lips, or in your mouth </li>
<li>severe rash with blisters or peeling skin </li>
<li>rash with itching </li>
<li>rash with fever 
Your doctor may need to prescribe medicines, including a steroid medicine, to treat your skin rash or 
other skin reactions. </li>
</ul>
<p>Inflammation of the lungs<br />
Copiktra can cause inflammation of your lungs which can be serious and can lead to death. Tell your 
doctor or pharmacist right away if you get new or worsening cough or difficulty breathing. Your 
doctor may do tests to check your lungs if you have breathing problems. Your doctor may treat you 
with a steroid medicine if you develop inflammation of the lungs that is not due to an infection. </p>
<p>Elevated liver enzymes 
Copiktra may cause abnormalities in blood tests for your liver. Your doctor will check for liver 
problems during your treatment with Copiktra. Tell your doctor right away if you get any symptoms of 
liver problems, including yellowing of your skin or the white part of your eyes (jaundice), abdominal 
pain, bruising or bleeding more easily than normal. </p>
<p>Blood counts 
Low white blood cell counts (neutropenia) and  decrease in red blood cell (anaemia or bloodlessness) 
can occur in patients treated with Copiktra. Both can be serious. Your doctor will check your blood 
counts regularly. Tell your doctor right away if you get fever or any signs of infection, if you feel tired 
or dizzy, or if you have headache. </p>
<p>If you have any of the above serious side effects during treatment with Copiktra, your doctor may 
pause your treatment, change your dose of Copiktra, or completely stop your treatment with Copiktra. </p>
<p>Children and adolescents 
Do not give this medicine to children and adolescents under 18 years of age because it has not been 
studied in this age group.  </p>
<p>Other medicines and Copiktra 
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other 
medicines. This is because Copiktra can affect the way some other medicines work and some other 
medicines can affect the way Copiktra works.  </p>
<p>Tell your doctor or pharmacist if you are taking any of the following medicines: </p>
<ul>
<li>alfentanil, fentanyl, methadone, buprenorphine/naloxone, medicines used for pain relief </li>
<li>alfuzosin, a medicine used to treat an enlarged prostate </li>
<li>amiodarone, bepridil, disopyramide, lidocaine, quinidine, medicines used to treat heart 
problems </li>
<li>amlodipine, diltiazem, felodipine, nicardipine, nifedipine, verapamil, medicines used to 
treat high blood pressure and heart problems </li>
<li>amprenavir, atazanavir, darunavir, efavirenz, etravirine, fosamprenavir, indinavir, 
lopinavir, nelfinavir, ritonavir, saquinavir, medicines used to treat HIV infections </li>
<li>aprepitant, a medicine used to prevent vomiting </li>
<li>boceprevir, telaprevir, medicines used to treat hepatitis C </li>
<li>bosentan, a medicine used to treat pulmonary hypertension, a lung disease that makes 
breathing difficult </li>
<li>budesonide, fluticasone, steroid medicines used to treat hayfever and asthma, and 
salmeterol, used to treat asthma </li>
<li>buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem, medicines used to 
treat nervous system disorders </li>
<li>carbamazepine, mephenytoin, phenytoin, medicines used to prevent seizures </li>
<li>ciclosporin, sirolimus, tacrolimus, medicines used to prevent organ rejection  after a 
transplant </li>
<li>ciprofloxacin, clarithromycin, erythromycin, nafcillin, telithromycin, medicines used to 
treat bacterial infections </li>
<li>cisapride, a medicine used to relieve certain stomach problems </li>
<li>colchicine, a medicine used to treat gout </li>
<li>conivaptan, a medicine to treat heart problems </li>
<li>dabigatran, warfarin, medicines used to prevent blood clots </li>
<li>dasatinib, imatinib, nilotinib, paclitaxel, vinblastine, vincristine, medicines used to treat 
cancer </li>
<li>dihydroergotamine, ergotamine, medicines used to treat migraine headache </li>
<li>fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole, medicines used to 
treat fungal infections </li>
<li>midazolam, triazolam, when taken by mouth to help you sleep or relieve anxiety </li>
<li>modafinil, a medicine used to treat excessive sleepiness </li>
<li>oral or implanted hormonal contraceptives, used to prevent pregnancy </li>
<li>pimozide, a medicine used to treat abnormal thoughts or feelings </li>
<li>quetiapine, a medicine used to treat schizophrenia, bipolar disorder and major depressive 
disorder </li>
<li>rifabutin, rifampicin medicines used to treat bacterial infections including tuberculosis </li>
<li>sildenafil, tadalafil, medicines used to treat impotence and pulmonary hypertension, a lung 
disease that makes breathing difficult </li>
<li>statin  medicines such as atorvastatin, lovastatin, simvastatin, used to lower cholesterol </li>
<li>St. John s wort (Hypericum perforatum), a herbal remedy used for depression and anxiety </li>
<li>trazodone, a medicine used to treat depression </li>
</ul>
<p>Copiktra with food and drink 
Avoid drinking grapefruit juice. Grapefruit juice can affect the way Copiktra works. </p>
<p>Pregnancy 
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for 
advice before taking this medicine. A pregnancy test should be conducted before taking Copiktra. </p>
<p>Use of Copiktra should be avoided during pregnancy.  </p>
<p>If you become pregnant during treatment with Copiktra, tell your doctor as soon as possible. </p>
<p>Breast-feeding </p>
<p>It is not known if Copiktra passes into breast milk. Do not breast-feed during treatment with Copiktra 
and for at least 1 month after the last dose. </p>
<p>Contraception 
Use effective contraception, which includes two forms of reliable contraception, during treatment and 
for at least 1 month after receiving the last dose of Copiktra.  </p>
<p>Contraceptive pills 
It is not known if Copiktra reduces the effectiveness of the contraceptive pill. If you are taking the 
contraceptive pill while you are being treated with Copiktra you also need to use a barrier method of 
contraception (such as condoms). Ask your doctor for advice. </p>
<p>Driving and using machines 
Copiktra is unlikely to affect your ability to drive and use machines. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take copiktra"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take copiktra"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not 
sure. </p>
<p>The recommended dose of Copiktra is 25 mg taken by mouth twice a day. However, your doctor may 
change your dose of Copiktra or ask you to stop taking Copiktra if you get particular side effects. Do 
not change your dose or stop taking Copiktra without talking to your doctor first. </p>
<p>Swallow Copiktra capsules whole.<br />
Do not open, break, or chew the capsules . You may take Copiktra with food or between meals.  Tell 
your doctor or caregiver if you have problems swallowing these capsules.  </p>
<p>If you take more Copiktra than you should 
If you take too much Copiktra, call your doctor or pharmacist right away or go to the nearest hospital 
emergency room. Take the medicine and this leaflet with you so that you can easily describe what you 
have taken. </p>
<p>If you forget to take Copiktra 
Take care not to miss a dose of Copiktra. If you miss a dose of Copiktra by less than 6 hours, take the 
missed dose right away, and then take the next dose at your usual time. If you miss a dose by more 
than 6 hours, wait and take the next dose at your usual time.  Do not take a double dose to make up for 
a forgotten capsule. </p>
<p>If you stop taking Copiktra 
Do not stop taking this medicine unless your doctor tells you to.  </p>
<p>If you have any further questions on the use of this medicine, ask your doctor.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Some side effects could be serious.  </p>
<p>Get medical help immediately if you experience any of the following: 
* Fever, chills, or other signs of an infection 
* New or worsening diarrhoea, stool with mucus or blood, or severe abdominal (stomach area) 
pain 
* New or worsening skin rash, or other skin reactions including 
 * painful sores or ulcers on your skin, lips, or in your mouth * severe rash with blisters or peeling skin * rash with itching and/or fever 
* New or worsening cough or difficulty breathing </p>
<p>Other side effects </p>
<p>Very common: may affect more than 1 in 10 people 
* Infections of the upper and lower respiratory tract, lung infection (pneumonia) 
* Decrease in some white blood cells (neutropenia) 
* Decrease in red blood cell (anaemia) 
* Decrease in cells in the blood that help the blood to clot (thrombocytopenia) 
* Decreased appetite 
* Headache 
* Shortness of breath (dyspnoea) 
* Cough 
* Inflammation of the intestines (colitis), diarrhoea (watery, loose or soft stools), vomiting, 
nausea, stomach pain 
* Difficulty passing stools (constipation) 
* Skin rash sometimes with blisters 
* Pain in the muscles, bones (musculoskeletal pain) and joints (arthralgia)<br />
<em> Fever<br />
</em> Feeling tired or weak<br />
* Increased level of a specific protein in blood that measures function of pancreas 
* Increased levels of liver enzymes seen in blood tests </p>
<p>Common: may affect up to 1 in 10 people 
* Infection can spread to vital organs causing the organs to not function properly (sepsis) 
* Inflammation of the lungs (pneumonitis, characterised by coughing and difficulty breathing) </p>
<p>Uncommon: may affect up to 1 in 100 people 
* Severe and possibly fatal peeling of the skin (toxic epidermal necrolysis, Stevens-Johnson 
syndrome, drug rash with increase in white blood cell counts (eosinophilia) and symptoms 
affecting the whole body) </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. 
By reporting side effects, you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store copiktra"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store copiktra"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. 
The expiry date refers to the last day of that month. </p>
<p>Store below 30 C. </p>
<p>Store in the original package in order to protect from light. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Copiktra contains<br />
- The active substance is duvelisib. Each hard capsule contains 15 mg or 25 mg duvelisib (as 
monohydrate). 
- The other ingredients are: 
Capsule content: colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline 
cellulose. 
Capsule shell: gelatin, titanium dioxide (E 171), red iron oxide (E 172). 
Printing black ink: shellac glaze, iron oxide black (E 172), propylene glycol,  ammonium 
hydroxide. </p>
<p>What Copiktra looks like and contents of the pack </p>
<p>Copiktra 15 mg hard capsules 
* Opaque pink capsule with  duv 15 mg  printed on the body in black ink. 
* Pack size: 28 days carton containing 56 capsules (2 blisters with 28 capsules each). </p>
<p>Copiktra 25 mg hard capsules 
* Opaque capsule with a white to off-white body and Orange cap with  duv 25 mg  printed on the 
body in black ink. 
* Pack size: 28 days carton containing 56 capsules (2 blisters with 28 capsules each). </p>
<p>Marketing Authorisation Holder 
Secura Bio Limited 
32 Molesworth Street 
Dublin 2<br />
Ireland </p>
<p>Manufacturer<br />
Millmount Healthcare Limited (trading as PCI Pharma Services) 
Block 7, City North Business Campus 
Stamullen, Co. Meath, K32 YDIreland </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-74778e8109bf478af8bf20ce15b25c4c
InstanceOf: CompositionUvEpi
Title: "Composition for copiktra Package Leaflet"
Description:  "Composition for copiktra Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpe9b880749c9b002511477c4f4dcdb6c9)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - copiktra"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Copiktra </li>
<li>Sådan skal du tage Copiktra </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What copiktra is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What copiktra is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Copiktra er et kræftlægemiddel, der indeholder det aktive stof duvelisib. Det virker ved at blokere 
virkningen af enzymer, som B-lymfocytter (en type hvide blodlegemer) er afhængige af for at kunne 
vokse og overleve. Disse enzymer er overaktive i visse ondartede hvide blodlegemer, og ved at 
blokere dem kan Copiktra dræbe og reducere antallet af ondartede B-lymfocytter. </p>
<p>Copiktra anvendes til behandling af ondartede B-lymfocytter ved kræftsygdommene 
• kronisk lymfatisk leukæmi (eller småcellet lymfocytært lymfom) 
• follikulær leukæmi. </p>
<p>Ved disse sygdomme formerer B-lymfocytterne sig for hurtigt og lever for længe, så der er for mange 
af dem i blodet eller lymfeknuderne. Copiktra anvendes hos patienter, der tidligere har fået mindst 
2 andre behandlinger, som ikke har virket, eller som ikke længere virker. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take copiktra"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take copiktra"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Copiktra 
- hvis du er allergisk over for duvelisib eller et af de øvrige indholdsstoffer i Copiktra (angivet i 
punkt 6). 
Er du i tvivl, så spørg lægen, før du tager Copiktra. </p>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen eller apotekspersonalet, før du tager Copiktra 
- hvis du har en infektion. Den skal behandles, før du begynder at tage Copiktra. 
- hvis du har tarmproblemer </p>
<ul>
<li>hvis du har lunge- eller vejrtrækningsproblemer </li>
</ul>
<p>Infektioner 
Infektioner er almindelige ved behandling med Copiktra, og de kan være alvorlige og have dødelig 
udgang. Kontakt lægen, apotekspersonalet eller sygeplejersken med det samme, hvis du får feber, 
kulderystelser eller andre tegn på infektion under behandling med Copiktra. Lægen kan ordinere anden 
medicin, mens du tager Copiktra, for at forebygge visse typer infektion. </p>
<p>Diarré eller betændelse i tarmen 
Diarré eller betændelse i tarmen (colitis) er almindeligt ved behandling med Copiktra, og de kan være 
alvorlige og have dødelig udgang. Kontakt lægen eller apotekspersonalet med det samme, hvis du får 
ny eller forværret diarré, har slimet eller blodig afføring eller får kraftige mavesmerter. Lægen eller 
apotekspersonalet bør ordinere medicin mod diarré og tjekke dig mindst en gang om ugen. Hvis din 
diarré er kraftig, eller hvis dit diarrémiddel ikke virker, skal du muligvis behandles med et steroid. </p>
<p>Hudreaktioner 
Copiktra kan give udslæt og andre hudreaktioner, der kan være alvorlige og have dødelig udgang. 
Kontakt lægen eller apotekspersonalet med det samme, hvis du får nye eller forværrede hududslæt eller 
andre hudreaktioner under behandling med Copiktra, herunder:</p>
<ul>
<li>smertefulde sår på huden, læberne eller i munden </li>
<li>kraftigt udslæt med blærer eller afskalning af huden </li>
<li>udslæt med kløe </li>
<li>udslæt med feber 
Lægen vil muligvis ordinere medicin, herunder et steroid, til behandling af dit udslæt eller andre 
hudreaktioner. </li>
</ul>
<p>Lungebetændelse 
Copiktra kan forårsage lungebetændelse, som kan være alvorlig og have dødelig udgang. Kontakt 
lægen eller apotekspersonalet med det samme, hvis du får ny eller forværret hoste eller 
vejrtrækningsproblemer. Lægen kan udføre test til undersøgelse af dine lunger, hvis du har 
vejrtrækningsproblemer. Lægen vil muligvis behandle dig med et steroid, hvis du udvikler 
lungebetændelse, der ikke skyldes en infektion. </p>
<p>Forhøjede levertal 
Copiktra kan give unormale levertal i blodprøver. Lægen vil tjekke dig for leverproblemer under 
behandlingen med Copiktra. Kontakt lægen med det samme, hvis du får symptomer på leverproblemer, 
herunder gulfarvning af huden eller det hvide i øjnene (gulsot), mavesmerter eller tendens til blå 
mærker eller blødning. </p>
<p>Blodtal 
Lavt antal hvide blodlegemer (neutropeni) og nedsat antal røde blodlegemer (anæmi eller blodmangel) 
kan ses hos patienter i behandling med Copiktra. Begge dele kan være alvorligt. Lægen vil tjekke dit 
blodtal regelmæssigt. Kontakt lægen med det samme, hvis du får feber eller tegn på infektion, føler dig 
træt eller svimmel eller får hovedpine. </p>
<p>Hvis du får en eller flere af ovenstående alvorlige bivirkninger under behandling med Copiktra, kan 
lægen sætte din behandling på pause, ændre din dosis eller helt standse din behandling med Copiktra. </p>
<p>Børn og unge 
Dette lægemiddel må ikke anvendes til børn og unge under 18 år, da det ikke er undersøgt i denne 
aldersgruppe. </p>
<p>Brug af anden medicin sammen med Copiktra 
Fortæl det altid til lægen, apotekspersonalet eller sygeplejersken, hvis du tager anden medicin, for 
nylig har taget anden medicin eller planlægger at tage anden medicin. Copiktra kan påvirke andre 
lægemidlers virkemåde, og visse andre lægemidler kan påvirke Copiktras virkemåde. </p>
<p>Fortæl det til lægen eller apotekspersonalet, hvis du tager et eller flere af følgende lægemidler: </p>
<ul>
<li>
<p>alfentanil, fentanyl, metadon, buprenorphin/naloxon - til lindring af smerter </p>
</li>
<li>
<p>alfuzosin - til behandling af forstørret prostata </p>
</li>
<li>
<p>amiodaron, bepridil, disopyramid, lidocain, quinidin - til behandling af hjerteproblemer </p>
</li>
<li>
<p>amlodipin, diltiazem, felodipin, nicardipin, nifedipin, verapamil - til behandling af 
forhøjet blodtryk og hjerteproblemer </p>
</li>
<li>
<p>amprenavir, atazanavir, darunavir, efavirenz, etravirin, fosamprenavir, indinavir, 
lopinavir, nelfinavir, ritonavir, saquinavir - til behandling af hiv-infektioner </p>
</li>
<li>
<p>aprepitant - til forebyggelse af opkastning </p>
</li>
<li>
<p>boceprevir, telaprevir - til behandling af hepatitis C </p>
</li>
<li>
<p>bosentan - til behandling af pulmonal hypertension (forhøjet blodtryk i lungerne, der giver 
vejrtrækningsbesvær) </p>
</li>
<li>
<p>budesonid, fluticason - steroider til behandling af høfeber og astma, og salmeterol til 
behandling af astma </p>
</li>
<li>
<p>buspiron, clorazepat, diazepam, estazolam, flurazepam, zolpidem - til behandling af 
forstyrrelser i nervesystemet </p>
</li>
<li>
<p>carbamazepin, mephenytoin, phenytoin - til forebyggelse af krampeanfald </p>
</li>
<li>
<p>ciclosporin, sirolimus, tacrolimus - til forebyggelse af organafstødning efter transplantation </p>
</li>
<li>
<p>ciprofloxacin, clarithromycin, erythromycin, nafcillin, telithromycin - til behandling af 
bakterieinfektioner </p>
</li>
<li>
<p>cisaprid - til lindring af visse maveproblemer </p>
</li>
<li>
<p>colchicin - til behandling af urinsyregigt </p>
</li>
<li>
<p>conivaptan - til behandling af hjerteproblemer </p>
</li>
<li>
<p>dabigatran, warfarin - til forebyggelse af blodpropper </p>
</li>
<li>
<p>dasatinib, imatinib, nilotinib, paclitaxel, vinblastin, vincristin - til behandling af kræft </p>
</li>
<li>
<p>dihydroergotamin, ergotamin - til behandling af migræne </p>
</li>
<li>
<p>fluconazol, itraconazol, ketoconazol, posaconazol, voriconazol - til behandling af 
svampeinfektioner </p>
</li>
<li>
<p>midazolam, triazolam - til behandling af søvnforstyrrelser eller lindring af angst (ved 
indtagelse gennem munden) </p>
</li>
<li>
<p>modafinil - til behandling af usædvanlig søvnighed </p>
</li>
<li>
<p>p-piller eller p-implantat - til forebyggelse af graviditet </p>
</li>
<li>
<p>pimozid - til behandling af unormale tanker eller følelser </p>
</li>
<li>
<p>quetiapin - til behandling af skizofreni, bipolar lidelse og svær depression </p>
</li>
<li>
<p>rifabutin, rifampicin - til behandling af bakterieinfektioner, herunder tuberkulose </p>
</li>
<li>
<p>sildenafil, tadalafil - til behandling af impotens og pulmonal hypertension (forhøjet blodtryk 
i lungerne, der giver vejrtrækningsbesvær) </p>
</li>
<li>
<p>statiner som f.eks. atorvastatin, lovastatin, simvastatin - til sænkning af 
kolesterolniveauet </p>
</li>
<li>
<p>Prikbladet perikum (Hypericum perforatum) - et naturlægemiddel mod depression og angst </p>
</li>
<li>
<p>trazodon - til behandling af depression </p>
</li>
</ul>
<p>Brug af Copiktra sammen med mad og drikke 
Undgå at drikke grapefrugtjuice. Grapefrugtjuice kan påvirke Copiktras virkemåde. </p>
<p>Graviditet 
Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge din 
læge til råds, før du tager dette lægemiddel. Der bør tages en graviditetstest inden brug af Copiktra. </p>
<p>Copiktra bør ikke anvendes under graviditet. </p>
<p>Hvis du bliver gravid under behandling med Copiktra, skal du underrette lægen så hurtigt som muligt. </p>
<p>Amning 
Det er ukendt, om Copiktra udskilles i human mælk. Du bør ikke amme under behandling med 
Copiktra og i mindst 1 måned efter den sidste dosis. </p>
<p>Prævention 
Sørg for sikker svangerskabsforebyggelse ved at anvende to sikre præventionsmetoder under 
behandling med Copiktra og i mindst 1 måned efter den sidste dosis. </p>
<p>P-piller 
Det vides ikke, om Copiktra nedsætter effekten af p-piller. Hvis du tager p-piller, mens du er i 
behandling med Copiktra, skal du også anvende en barrieremetode (f.eks. kondom). Spørg lægen til 
råds. </p>
<p>Trafik- og arbejdssikkerhed 
Copiktra forventes ikke at påvirke din evne til at føre motorkøretøj og betjene maskiner. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take copiktra"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take copiktra"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen. </p>
<p>Den anbefalede dosis Copiktra er 25 mg taget gennem munden to gange dagligt. Lægen kan dog ændre 
din dosis af Copiktra eller bede dig om at stoppe med at tage Copiktra, hvis du får visse bivirkninger. 
Du må ikke ændre din dosis eller holde op med at tage Copiktra uden først at tale med lægen. </p>
<p>Synk Copiktra-kapslerne hele. 
Du må ikke åbne, knuse eller tygge kapslerne. Du kan tage Copiktra med eller uden mad. Sig det til 
lægen eller din omsorgsperson, hvis du har problemer med at sluge kapslerne. </p>
<p>Hvis du har taget for meget Copiktra 
Hvis du har taget for meget Copiktra, skal du straks kontakte lægen eller apotekspersonalet eller tage 
til den nærmeste skadestue. Tag medicinen og denne indlægsseddel med, så du let kan beskrive, hvad 
du har taget. </p>
<p>Hvis du har glemt at tage Copiktra 
Du skal være omhyggelig med ikke at glemme en dosis Copiktra. Hvis det er under 6 timer siden, du 
skulle have taget din dosis Copiktra, skal du tage den glemte dosis med det samme og så tage den 
næste dosis på det sædvanlige tidspunkt. Hvis det er over 6 timer siden, skal du vente med at tage en 
dosis til det næste planlagte doseringstidspunkt. Du må ikke tage en dobbeltdosis som erstatning for en 
glemt kapsel. </p>
<p>Hvis du holder op med at tage Copiktra 
Du må ikke holde op med at tage dette lægemiddel, medmindre lægen siger, du skal. </p>
<p>Spørg lægen, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Nogle bivirkninger kan være alvorlige. </p>
<p>Du skal søge lægehjælp med det samme, hvis du får et eller flere af følgende symptomer: </p>
<ul>
<li>
<p>Feber, kulderystelser eller andre tegn på infektion </p>
</li>
<li>
<p>Ny eller forværret diarré, slimet eller blodig afføring eller kraftige mavesmerter </p>
</li>
<li>
<p>Nyt eller forværret udslæt eller andre hudreaktioner, herunder </p>
</li>
<li>
<p>smertefulde sår på huden, læberne eller i munden * kraftigt udslæt med blærer eller afskalning af huden * udslæt med kløe og/eller feber </p>
</li>
<li>
<p>Ny eller forværret hoste eller vejrtrækningsbesvær </p>
</li>
</ul>
<p>Andre bivirkninger </p>
<p>Meget almindelige bivirkninger: kan forekomme hos mere end 1 ud af 10 patienter </p>
<ul>
<li>
<p>Infektioner i de øvre og nedre luftveje, lungebetændelse (pneumoni) </p>
</li>
<li>
<p>Nedsat antal af visse hvide blodlegemer (neutropeni) </p>
</li>
<li>
<p>Nedsat antal røde blodlegemer (blodmangel) </p>
</li>
<li>
<p>Nedsat antal blodplader (medvirker til blodets størkning) (trombocytopeni) </p>
</li>
<li>
<p>Nedsat appetit </p>
</li>
<li>
<p>Hovedpine </p>
</li>
<li>
<p>Åndenød (dyspnø) </p>
</li>
<li>
<p>Hoste </p>
</li>
<li>
<p>Betændelse i tarmen (colitis), diarré (vandig, løs eller blød afføring), opkastning, kvalme, 
mavesmerter </p>
</li>
<li>
<p>Forstoppelse </p>
</li>
<li>
<p>Hududslæt, evt. med blærer </p>
</li>
<li>
<p>Smerter i muskler, knogler og led </p>
</li>
<li>
<p>Feber </p>
</li>
<li>
<p>Træthed eller svaghed </p>
</li>
<li>
<p>Øget niveau af et specifikt protein i blodet, der siger noget om bugspytkirtlens funktion. </p>
</li>
<li>
<p>Forhøjede levertal i blodprøver </p>
</li>
</ul>
<p>Almindelige bivirkninger: kan forekomme hos op til 1 ud af 10 patienter </p>
<ul>
<li>
<p>Infektion kan sprede sig til de vitale organer, så de ikke fungerer ordentligt (sepsis) </p>
</li>
<li>
<p>Lungebetændelse (pneumonitis, karakteriseret ved hoste og vejrtrækningsbesvær) </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger: kan forekomme hos op til 1 ud af 100 patienter </p>
<ul>
<li>Alvorlig og potentielt dødelig afskalning af huden (toksisk epidermal nekrolyse, Stevens-
Johnsons syndrom, lægemiddeludslæt med forhøjet antal hvide blodlegemer (eosinofili) og 
symptomer, der påvirker hele kroppen) </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge. Dette gælder også mulige bivirkninger, som 
ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette bivirkninger 
direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. Ved at 
indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette 
lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store copiktra"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store copiktra"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og blisterpakningen efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevares ved temperaturer under 30 °C. </p>
<p>Opbevares i den originale pakning for at beskytte mod lys. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Copiktra indeholder:</p>
<ul>
<li>Aktivt stof: duvelisib Hver hård kapsel indeholder 15 mg eller 25 mg duvelisib (som monohydrat). </li>
<li>
<p>Øvrige indholdsstoffer:</p>
</li>
<li>
<p>Kapselindhold: kolloidt siliciumdioxid, crospovidon, magnesiumstearat, mikrokrystallinsk 
cellulose. </p>
</li>
<li>Kapselskal: gelatine, titandioxid (E171), rød jernoxid (E172). </li>
<li>Sort trykfarve: shellacglasur, sort jernoxid (E172), propylenglycol, ammoniumhydroxid. </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Copiktra 15 mg hårde kapsler </p>
<ul>
<li>
<p>Uigennemsigtig, lyserød kapsel præget med "duv 15 mg" i sort blæk på underdelen. </p>
</li>
<li>
<p>Pakningsstørrelse: 28-dages æske indeholdende 56 kapsler (2 blisterkort med 28 kapsler i hver). </p>
</li>
</ul>
<p>Copiktra 25 mg hårde kapsler </p>
<ul>
<li>
<p>Uigennemsigtig kapsel med hvid til råhvid underdel, orange overdel og præget med "duv 25 mg" 
i sort blæk på underdelen. </p>
</li>
<li>
<p>Pakningsstørrelse: 28-dages æske indeholdende 56 kapsler (2 blisterkort med 28 kapsler i hver). </p>
</li>
</ul>
<p>Indehaver af markedsføringstilladelsen 
Secura Bio Limited<br />
32 Molesworth Street<br />
Dublin 2<br />
Irland </p>
<p>Fremstiller 
Millmount Healthcare Limited (trading as PCI Pharma Services) 
Block 7, City North Business Campus 
Stamullen, Co. Meath, K32 YDIrland </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-74778e8109bf478af8bf20ce15b25c4c
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for copiktra Package Leaflet for language en"
Description: "ePI document Bundle for copiktra Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-74778e8109bf478af8bf20ce15b25c4c"
* entry[0].resource = composition-en-74778e8109bf478af8bf20ce15b25c4c

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp74778e8109bf478af8bf20ce15b25c4c"
* entry[=].resource = mp74778e8109bf478af8bf20ce15b25c4c
                            
                    
Instance: bundlepackageleaflet-da-74778e8109bf478af8bf20ce15b25c4c
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for copiktra Package Leaflet for language da"
Description: "ePI document Bundle for copiktra Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-74778e8109bf478af8bf20ce15b25c4c"
* entry[0].resource = composition-da-74778e8109bf478af8bf20ce15b25c4c

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp74778e8109bf478af8bf20ce15b25c4c"
* entry[=].resource = mp74778e8109bf478af8bf20ce15b25c4c
                            
                    



Instance: mp74778e8109bf478af8bf20ce15b25c4c
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Copiktra 15 mg hard capsules"
Description: "Copiktra 15 mg hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/21/1542/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Copiktra 15 mg hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 74778e8109bf478af8bf20ce15b25c4cListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "copiktra"

* status = #current
* mode = #working

* title = "List of all ePIs associated with copiktra"

* subject = Reference(mpe9b880749c9b002511477c4f4dcdb6c9)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#copiktra "copiktra"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-74778e8109bf478af8bf20ce15b25c4c) // copiktra en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-74778e8109bf478af8bf20ce15b25c4c) // copiktra da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-74778e8109bf478af8bf20ce15b25c4c
InstanceOf: List

* insert 74778e8109bf478af8bf20ce15b25c4cListRuleset
    